Answers are grounded in this paper and cite their sources.
Case report shows pulmonary aspergillosis in a patient with rheumatoid arthritis on etanercept, indicating infection risk with TNF-a inhibitors.
Tumor necrosis factor (TNF-a) is a pro-inflammatory cytokine shown to play a significant role in the pathophysiology of various autoimmune diseases including rheumatoid arthritis (RA). Mechanistically TNF-a plays an important role in tumor suppression by inhibiting angiogenesis, stimulating immune cell production and increasing vascular leak. TNF-α inhibitors such as Etanercept have exhibited clinical benefit for treatment of RA; however, a small risk of opportunistic infections exists (7.9% risk of PFI [1]). Pulmonary Aspergillosis (PA) is more common in patients with hematologic malignancies, HCT recipients and patients with granulocytopenia. Only a few cases have been reported, in conjunction with Etanercept use in patients with RA. Herein we report a rare case of cystic bronchiectasis and PA in a similar scenario. Our patient, a 47 years old female, presented to her PCP for evaluation of worsening exertional dyspnea 10 months ago. PMH includes RA, anemia of chronic disease, hypertension and allergic rhinitis. The patient was treated with Leflunomide for approximately 5 years and was subsequently switched to Etanercept 2 years prior (by her rheumatologist) in view of anemia. Her symptoms were attributed to a large hiatal hernia apparent on CXR. Her ongoing symptoms prompted CT chest which revealed right lower lobe cystic bronchiectatic changes with mass like densities measuring 1.9 cm, and a large left sided paraesophageal hernia (Figure 1). Prior imaging was not available. Given persistence on imaging for 5 months, bronchoscopy with EBUS guided transbronchial needle aspirate and biopsy with BAL was performed. BAL positive for Aspergillus antigen ( > =3.750) and fungal cultures from biopsy confirmed Aspergillus fumigatus. The patient was started on Voriconolozole and Etanercept was discontinued. PFTS demonstrated severe airflow obstruction with a z-score for FEV1 -4.93, hyperinflation and preserved DLCO. Although rare, physicians must display high clinical suspicion for PA in patients on TNF-a inhibitors due to the high morbidity and mortality risk (up to 80% mortality risk [2]), particularly in patients with comorbidities and pre-existing pulmonary disease. As obstructive lung disease is a notable risk factor for PA, pre-screening patients with PFTS prior to Etanercept therapy may help in risk stratification. References: 1. Li, J.et.al Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis. Frontiers in Immunology, 16. 2. Li X, Lau SK, Woo PC. Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. Exp Biol Med (Maywood). 2020 Jul;245(13):1104-1114 This abstract is funded by: None
No takes yet. Share an insight, caveat, or question.
Samara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: